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Sample size re-assessment leading to a raised




Background: Onemajor concern with adaptive designs, such as the sample size adjustable designs, has been the fear
of inflating the type I error rate. In (Stat Med 23:1023-1038, 2004) it is however proven that when observations follow a
normal distribution and the interim result show promise, meaning that the conditional power exceeds 50%, type I
error rate is protected. This bound and the distributional assumptions may seem to impose undesirable restrictions on
the use of these designs. In (Stat Med 30:3267-3284, 2011) the possibility of going below 50% is explored and a region
that permits an increased sample size without inflation is defined in terms of the conditional power at the interim.
Methods: A criterion which is implicit in (Stat Med 30:3267-3284, 2011) is derived by elementary methods and
expressed in terms of the test statistic at the interim to simplify practical use. Mathematical and computational details
concerning this criterion are exhibited.
Results: Under very general conditions the type I error rate is preserved under sample size adjustable schemes that
permit a raise. The main result states that for normally distributed observations raising the sample size when the result
looks promising, where the definition of promising depends on the amount of knowledge gathered so far, guarantees
the protection of the type I error rate. Also, in the many situations where the test statistic approximately follows a
normal law, the deviation from the main result remains negligible. This article provides details regarding the Weibull
and binomial distributions and indicates how one may approach these distributions within the current setting.
Conclusions: There is thus reason to consider such designs more often, since they offer a means of adjusting an
important design feature at little or no cost in terms of error rate.
Keywords: Adaptive trial design, Type I error, Conditional power
Background
The last few years interest in various adaptive trial designs
has surged [1]. A greater flexibility of clinical study design
and conduct has followed from the application of these
new ideas [2]. In [1] adaptive designs are defined as:
“...a clinical trial design that allows adaptations or
modifications to aspects of the trial after its initiation
without undermining the validity or integrity of the
trial. ”
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More and more trials of this sort are being reported and
regulatory bodies take an increasingly favourable view on
them [3]. All stand to win if these designs come to optimal
use [4]. However, some concerns have been raised. One
of these involve the risk of inflating type I error. The cur-
rent article will assess that risk in the context of sample
size adjustable (SSA) designs that allow choosing between
raising the sample size, continuing as originally planned,
or closing the trial due to futility.
The following will recapitulate parts of [5], add detail
and draw conclusions for trial procedures. In that ref-
erence the authors show that if the interim results look
promising, no inflation of type I error rate occurs. Here
’promising’ means that the conditional power at the cur-
rent parameter estimate, i.e. the power updated by the
© 2013 Broberg; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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accumulated knowledge at interim, amounts to at least
50%. This article will show that a less strict bound applies,
in agreement with [6], exhibit the bound in terms of a test
statistic, and present mathematical as well as computa-
tional aspects of it.
Methods
Assumptions
Denote the planned final sample size by N0, the number
of patients available at the pre-planned interim analysis by
n, and the possible raise determined at the interim tak-
ing conditional power into account by r. Let us consider a
one-sided test at level α based on observingX1, . . . ,XNfinal .
Here Nfinal = N0 or Nfinal = N = N0 + r, depending
on a decision taken during the course of the trial. The
main result assumes normal distribution, but as will be
outlined, it will still hold true for more general distribu-
tions. Further, assume the Xi to be independent normal
with mean θ and variance 1. The null hypothesis states
that θ = 0. Define the normalised test statistic Z(x) by
Z(x) = ∑xi=1 Xi/√x. The test rejects if Z(Nfinal) > zα ,
where zα is the 100×(1−α) percentile of the standard nor-
mal distribution: (zα) = 1 − α ( being the cumulative
distribution function of the standard normal distribu-
tion). The normalised test statistic Z(n) = ∑ni=1 Xi/√n
is observed when n patients have provided data, and the
Data Monitoring Committee (DMC) will in part base its
recommendations on the observed value. At this interim
analysis an adaptation may lead to closing the study due
to futility, continuing the study without changes or raising
the sample size by recruiting an extra r subjects, yield-
ing a total of N = N0 + r subjects. Closing the study
due to futility may only decrease the type I error rate.
So let us, for the sake of argument, disregard that pos-
sibility, and show that the type I error rate still remains
protected.
The study protocol will specify n and N0, and at the
interimwe will consider raising the final sample size based
on the conditional power evaluated at the current param-
eter estimate. Since the objective is to assess if the interim
results are promising the current estimate of the param-
eter of interest gives the appropriate information [6]. As
pointed out by Müller and Schäfer in [7], the over-all type
I error can be preserved unconditionally under any gen-
eral adaptive change, provided the conditional type I error
that would have been obtained had there been no adapta-
tion is preserved. This article however only considers the
case of SSA. Unlike the situation in [8] the design does not
permit sequential testing. Also, the article only consid-
ers the conventional hypothesis tests and p-values without
adjustments.
We assess the conditional error rate as a function of r. By
showing that the conditional type I error rate is bounded
by the error rate which arises from the design without
adaptation the unconditional error rate is proven to be
controlled at a pre-specified level α.
Derivation of the main result
We use the notation X ∼ N(μ, σ 2) to signify that X
follows a normal law with mean μ and variance σ 2.
The change in type I error rate conditional on a sam-
ple size increase decided at the interim equals G(r) =
Pr(Z(N0+r) > zα|Z(n) = z, θ = 0) − Pr(Z(N0) >
zα|Z(n) = z, θ = 0). The conditional distribution equals
(Z(N)|Z(n) = z, θ = 0) ∼ N(ρz, 1 − ρ2), where
ρ = Cov(∑Ni=1 Xi/√N ,∑nj=1 Xj/√n) = ∑ni=1 1/√nN =√n/N , and similarly for Z(N0).



















Now, in order to show this difference to be less than
or equal to zero it may be equivalently shown that the
difference of the arguments is negative (in the sense of
non-positive), and denote this by H(r). Obviously H(0) =
0.
To simplify notation put q = n/(N0 + r) and V = (N0 +
r)/N0 for arbitrary n,N0 and r, satisfying N0 > n > 0, and
r > 0. Please note qV = n/N0. Then we aim to show
√qz − zα√1 − q −
√qVz − zα√1 − Vq ≤ 0
This implies
z




( 1√1 − q −
1√1 − qV
)
And, then, multiply by −1 and divide by the multiplier
of z, to obtain
z ≥ zα
√1 − q− √1 − qV√1 − q√1 − qV
/√qV√1 − q − √q√1 − qV√1 − q√1 − qV ,
which after cancelling out √1− q√1 − qV becomes
z ≥ zα(
√
1−q−√1−qV )/(√qV√1−q− √q√1−qV )
:= zαb(q,V )
(1)
Now let us compare this bound to zα
√n/N0. Denote the
bound in (1) by zαb(q,V ), and set out to prove b(q,V ) ≤√qV . By subtracting √qV from both sides and equating
denominators we have
√1−q−√1−qV−√qV (√qV√1−q−√q√1−qV )√qV√1−q−√q√1−qV ≤0
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But the denominator is positive under current assump-
tions. Thus, we may disregard it, and thus, we need to
prove
√
1 − q(1 − qV ) +√1 − qV (q√V − 1) ≤ 0
Division by√1 − qV , moving the right term to the right
hand side of the inequality symbol, and squaring both
sides yields
(1 − q)(1 − qV ) ≤ 1 − 2q√V + q2V
By expanding the left hand side product, eliminating
terms and multiplying both sides by −1/q, we finally have
V + 1 ≥ 2√V ,
which is true for all positive V.
Now regard b as a function of r for n and N0 fix. One
may show that, b(r) ↗ √n/N0 asymptotically as r ↘ 0.
Further, b decreases as r grows in a close to linear fashion.
Also, b(r) ↘ (1−√1 − qV )/√qV when r tends to infinity.
Please note that since the b(q,V ) ≤ √qV = √n/N0 a
sufficient but not necessary condition is z ≥ zα√n/N0,
which will be seen to give the conditional power 50% (the
simple criterion). Consequently, this new criterion is less
restrictive than the one presented in [5], and, importantly,
changes with r. The reference [6] provides an example
where the type I error remains intact although the condi-
tional power descends down to 36%.
To obtain the conditional power please note that
E[Z(N0)|Z(n) = z, θ = z/√n]= z/√n/N0, and further-
more (Z(N0)|Z(n) = z, θ = z/√n) ∼ N(z/√n/N0, 1 −
n/N0). Then
Pr[Z(N0) > zα|Z(n) = z, θ = z/√n]







The minimum of this probability over z > b(q,V )zα
equals

(zα(b(q,V )/√qV − 1)√1 − qV
)
From the definition ofG(r) it follows that one cannot go
further without increasing the conditional error rate. In
this sense the bound is optimal.
Weibull ditributed survival time points
We will now study the situation where survival times fol-
low aWeibull distribution and right censoring time points
are exponentially distributed.
In [9] the details of an Edgeworth expansion of the prod-
uct limit estimator are given (x) − n− 12 φ(x)(κ˜3(x2 −
1) + 3σ1)/6. First some notation: X = lifetime, T = left
truncation time point, Y = right censoring time point,
Z = min(X,Y ), δ = I(X ≤ Y ). Further, put C(z) :=
P(T ≤ z ≤ Z|T ≤ Z). But since T ≡ 0 this probability
equals P(Z ≥ z) = P(X ≥ z,Y ≥ z) = P(X ≥ z)P(Y ≥ z).





C2(u) , the constant κ˜3 in the Edgeworth
expansion equals σ−11
(−7.5σ 41 + ∫ z0 C−3(t)dW1(t)). As
stated we assume X ∼ Weib(λ, β) and Y ∼ Exp(μ).
From this follows that C(y) = exp(−μy − λyβ), W1(y) =∫ y
0 e−μxλβxβ−1e−λx
βdx. Thus one may at the interim use
parameter estimates to calculate a normal approximation
to the conditional power. Alternatively, one may simulate
the remainder of the trial. A third option is to base the
procedure on the logrank test whose statistic converges
to a normal distribution. Consider the situation where the
time to some event is compared between patients in an
active treatment group and those in a control group. Let ri
refer to the number of patients remaining at time i and oi
refer to the number of observed events. Further, letA refer
to the active treatment group and C to the control group.






then z = T/√V will asymptotically be standard normal,
e.g. [10]. Hence one may apply the simple criterion to z
observed at the interim.
Binomial proportion
For the sake of simplicity of exposition we focus atten-
tion to a single binomial proportion p and a one-sided
test at the 5% level. Let the null hypothesis and alternative
hypothesis be H0 : p = p0,H1 : p > p0. Please note that
for XN0 ∼ Bin(N0, p0) the conditional distribution given
{Xn = k} is the same as XN0−n + k ∼ Bin(N0 − n, p0), and
similarly for XN0+r .
From this follows that we may obtain G(r) exactly: in
terms of R code [11]
#let the level of the test be 5%
qs.r <-qbinom(p = 0.95, size = N0+r,
prob = p0)
qs <- qbinom(p = 0.95, size = N0, prob = p0)
G.r <- pbinom(qs-k,size = N0-n,prob = p0)-
pbinom(qs.r - k, size = N0+r-n, prob = p0)
However, we will look at a normal approximation. In the
binomial case several test statistics with close to normal
distribution exist:
1. the score test statistic:
z = √n(pˆ − p0)/
√
p0(1 − p0)), pˆ = k/n
2. the log-odds:
z = √npˆ(1 − pˆ) (log(pˆ/(1 − pˆ)) − log(p0/(1 − p0)))
[12]
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N0 zα , then the procedures protects the type I
error rate (unconditionally). But we set out to find a more
accurate approximation.
Now using the condition {Xn = k}
G(r) =Pp0(XN0+r−n > qα,N0+r − k)
− Pp0(XN0−n > qα,N0 − k),
where qα,m is the 100 × (1 − α) percentile of Bin(m, p0).
Also the binomial distribution Xn ∼ Bin(n, p) admits
a normal approximation of the pivotal statistic U =
(Xn−E[Xn] )/SD(Xn), which coincides with the score test
statistic above, such that
P(U > q) = 1−
(








in terms of the third cumulant of U, which picks up the
skewness. As a rule of thumb it is often said that the nor-
mal approximation is quite accurate when np and n(1−p)
both exceed 5. But this statement holds even without the
correction with respect to skewness.
In this case we may approximate the difference G(r)
defined above by
G(r) =Pp0(XN0+r > qα,N0+r|Xn = k)
− Pp0(XN0 > qα,N0 |Xn = k),
where we insert the percentiles obtained from the inver-
sion of the Cornish-Fisher expansion, cf. e.g. [13]:
qα,n = μn + √nσ0(zα + γ06√n (z
2
α − 1)),
denoting μn = np0, σ0 =
√
p0(1 − p0), and the third
cumulant (1 − 2p0)/σ0 by γ0. This quantity will deviate
less than 1 from the true percentile for n from 20 to 200,
andmin{np0, n(1−p0)} > 5. Let us consider G(r) through
the pivotal quantities
UN = qα,N − k − μN−n
σN−n
We will be concerned with the difference
UN0+r − UN0 =
qα,N0+r − k − μN0+r−n
σN0+r−n
− qα,N0 − k − μN0−n
σN0−n
The task is now to identify when this difference is pos-
itive. To simplify notation denote by n1 the larger of the
two sample sizes and by n2 the smaller. After equating the




np0 + √n1zασ0 + γ0σ0(z2α − 1)/6 − k
)
√




np0 + √n2zασ0 + γ0σ0(z2α − 1)/6 − k
)
√
(n1 − n)(n2 − n)σ0








+(√n2 − n√n1 − √n1 − n√n2)zασ0 > 0
Some algebra will unearth the condition





√n2 − n√n1 − √n1 − n√n2)zασ0√n2 − n − √n1 − n
Please note that the first term corresponds to expecta-
tion of the null distribution. Further, the second term will
be negative if p0 > 0.5, and the third will always be nega-
tive under the conditions of this paper. From this follows
that the normal approximation of G(r) is non-positive
for k satisfying the above condition. Finally, invoke the
fast convergence of the binomial distribution towards a
normal law, which means that already 20 observations
will make the normal approximation quite accurate, pro-
vided min{np, n(1 − p)} > 5. Simulations indicate that
this decision rule is accurate already at an interim sample
size n as low as 20. However, the rule does not guar-
antee preservation of the conditional type I error rate
for all p. Thus the conclusion is that for the binomial
distribution there is no inflation of the unconditional
type I error rate under the above conditions. A total of
900000 simulations with n from 20 to 100, p0 picked
randomly in [ 5/n, 1 − 5/n], k randomly generated from
Bin(n, p0) and N0 = 2n and r = n gave a median and
mean of G(r) equal to −0.004762 and −0.004574, respec-
tively, over the set defined by the inequality above. A set
of similar simulations using the simple criterion (k >
n(p0 +
√
p0(1 − p0))/N0zα) gave median and mean equal
to −0.02429 and −0.02389, respectively. Thus the simple
criterion will be on the conservative side.
Results
Main result
InMethods the following result was derived.
A conditional power that quarantees preservation of nominal
significance level
If the conditional power at the interim, which occurs after
n out N0 planned observations and leads to a raise of r,
equals at least

(zα(b(q,V )/√qV − 1)√1 − qV
)
, (2)
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where q = n/(N0 + r), V = (N0 + r)/N0, and
b(q,V ) = (√1−q−√1−qV )/(√qV√1−q−√q√1−qV ),
(3)
then the type I error rate is preserved. The function b sat-
isfies the inequalities (1 − √1 − qV )/√qV ≤ b(q,V ) ≤√qV = √n/N0.
A more practical criterion, or rule of thumb, may be to
derive a test statistic z with close to a standard normal




N0 zα . This will be referred to as the simple crite-
rion, and stems from [5]. More generally, the condition
z > b(q,V )zα suffices (cf. equations (11) and (12) in
[6]). The conditional power bound in (2) decreases as r
increases, but the lower bound on b implies a limit.
Example
Take the example of n = 55,N0 = 110, r = 40 and
α = 0.025, zα = 1.96. Then the minimum conditional
power equals 43%, see next subsection. Thus a conditional
power of considerably less than 50% is permissible from
the point of view of type I error rate preservation. This
may be good to know if the original sample size calcu-
lation was grossly wrong. Then recruiting more subjects
than planned may resolve the issue without jeopardising
the type I error rate. On the other hand, in such a situation
the validity of the scientific hypotheses on which the trial
design rests may be questioned, and the sponsor will have
to judge whether the updated hypotheses suggest a com-
mercially viable route. Nevertheless, in some cases raising
the sample size will make sense, and may save the trial
from unnecessary disaster.
Above we assume the variance to be known. If it is not
we may estimate it and use for instance a t-test statistic
which quickly converges to a normal as the sample size
increases.
Examination of the t-test has provided evidence of a
small degree of inflation [14]. In [15] further details of
when inflation occurs are given. However, already at a
sample size of 30 the t-distribution and the normal distri-
bution appear almost identical.
Calculations in R
In the statistical software environment R [11] one may
easily define functions. Let us regard the bound zαb(q,V )
as a function of (n,N0, r) instead. We may explore the
bound zαb(n,N0, r) through the R function B.func
B.func <- function(n, N0, r){q <- n/(N0+r);
V <- (N0+r)/N0;(sqrt(1-q)-sqrt(1-q*V))/
(sqrt(q*V)*sqrt(1-q)-sqrt(q)*sqrt(1-q*V))}
and, the minimum conditional power through
CP.min <- function(alpha1, n, N0, r){
za <- qnorm(1-alpha1)
q <-n/(N0+r);V <-(N0+r)/N0
b <- B.func(n = n, N0 = N0, r = r)
pnorm(za*(b/sqrt(q*V)-1)/sqrt(1-q*V))}
So, for instance CP.min(alpha1 = 0.025, n = 55, N0=110,
r = 40) = 0.43, and, B.func(n = 55, N0 = 110, r =
0.01) = 0.7070907, which approximately equals √n/N0 =√55/110 ≈ 0.7071068. Also CP.min(alpha1 = 0.025, n =
55, N0 = 110, r = 110) = 0.3575873.
Deviations from normal distribution
If we use non-normal data such as survival type of data,
then it is often possible to approximate the test statis-
tic by a normal variate. Many test statistics, e.g. those
derived by the maximum likelihood method, converge
quickly to a normal distribution when the sample size
increases. This feature extends the relevance of the main
result to measurements following other distributions than
the normal.
In Methods we looked into the situation where a
Kaplan-Meier (KM) estimate is used. The Edgeworth
expansion of the distribution of the (standardised) KM
estimator has the form(x)−n− 12 φ(x)κ˜3(x2−1)/6, where
κ˜3 is specified in Methods [9,16],  the cumulative dis-
tribution function of a standard normal variate and φ its
frequency function. So if we express the change in condi-
tional error rate (G(r) below) in terms of this expansion
the correction term to difference between normal distri-
bution functions will approach zero as 1/√n. Assuming
some parametric distribution, such as the Weibull dis-
tribution, one may work out the details regarding this
approximation. Or, one may assess the deviation from
normality through a simulation procedure.
In the case of a single binomial proportion p and a one-
sided test of the null hypothesis H0 : p = p0 versus the
alternative hypothesis p > p0, it holds that if we at the
interim observe Xn = k satisfying






N0 − n√n1 − √n1 − n√N0)zασ0√
N0 − n − √n1 − n ,
with σ0 = p0(1− p0), γ0 = (1− 2p0)/σ0 and n1 = N0 + r,
then inflation of the type I error rate will not occur. More
precisely put: on average , over all possible outcomes, the
procedure will preserve the type I error rate. However,
the conditional error rate will not always fall below the
nominal one.
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Discussion
There are operational issues with adaptive designs that
must be addressed during the planning stage. In order
to safeguard the integrity of the trial and avoid opera-
tional bias following an unblinded interim precautions
need to be put in place to limit access to both the results
and, even, the analysis plans. The latter will specify the
output and decision rules, but will leave open the pos-
sibility of including other information, such as external
factors in the final decision whether to stop for futility
or to continue, and if so, whether or not to raise the
sample size.
Further, a number of concerns have been raised involv-
ing the risk of violating statistical principles or lack
of efficacy compared to group sequential designs, e.g.
[17-19].
However valid these objections may be, more and more
practitioners have felt that the challenges are tractable and
have found SSA designs an attractive option. For small
biotechnology companies this option gives the possibility
of starting a trial with rather limited resources, followed
by an additional investment conditional on the interim
results being promising. Also, the SSA design makes a
lot of sense whenever a fix size design would have to
rely on quite limited amount of information regarding the
primary variable.
Several references have argued the superiority of seam-
less phase II/III designs over the traditional phase II and
III trials. Merging the two phases produces gains in valu-
able time [20], and, under reasonable conditions, saves
sample size [21].
Earlier research has established that a conditional power
at the interim analysis exceeding 50% implies that the con-
ditional, and hence also the unconditional, type I error
rate is preserved, cf. [5,7]. Further, the reference [6] builds
on [8] and others to identify a more general region where
this happens. The region is identified through equations
(11) and (12) in [6]. The derivation of the region relies
on results for Brownian motion. Together these two
equations implicitly define a bound that coincides with b
in (3) above.
Further, one cannot use a lower bound without
risking inflation of the conditional error rate, and
thus one may not rely on the Müller-Schäfer prin-
ciple of conditional error functions [7] (new does
not exceed the original) to prove preservation of
unconditional error rate1. By virtue of the Müller-
Schäfer principle of conditional error functions any
interim decision rule, pre-defined or not, that does
not violate this fundamental requirement will permit a
redesign of the trial. So from this perspective the SSA
designs described here are well behaved and offer great
flexibility.
Conclusions
This article has shown that the risk of compromising the
nominal significance level of a statistical test by allow-
ing a sample size increase during the course of a trial
remains low and controllable. The conditional error rate
and power provide key decision tools.
Endnotes
1 Also, by reversing the order of terms in G(r) and
tracing the same line of thought one may conclude that a
sample size decrease is permissible when results are
discouraging. But then it may make more sense to
discontinue the trial due to futility.
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